comparemela.com

Latest Breaking News On - Biosimilar medicines - Page 1 : comparemela.com

Penetration rate of generic and biosimilar drugs in Tunisia estimated at 55%

Penetration rate of generic and biosimilar drugs in Tunisia estimated at 55%
tanzanianewsreports.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tanzanianewsreports.com Daily Mail and Mail on Sunday newspapers.

Tunis
S26
Tunisia
Mehdi-dridi
World-health-organisation
World-bank
International-name
International-days-of-generic
Central-pharmacy
Tunisia-mehdi-dridi
International-days
Biosimilar-medicines


tap.info.tn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tap.info.tn Daily Mail and Mail on Sunday newspapers.

Tunisia
Tunis
S26
Mehdi-dridi
International-days-of-generic
International-name
World-bank
World-health-organisation
Central-pharmacy
Tunisia-mehdi-dridi
International-days
Biosimilar-medicines

Samsung Bioepis Gains European Commission Approval For PYZCHIVA, a Biosimilar to Stelara (Ustekinumab)

Samsung Bioepis Gains European Commission Approval For PYZCHIVA, a Biosimilar to Stelara (Ustekinumab)
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United-states
United-kingdom
Switzerland
Canada
Dennis-riedl
Samsung-bioepis
Samsung-bioepi
Byoungin-jung
Linkedin
Regulatory-affairs-team-leader
European-commission
Johnson

Changes to drug patent rules could affect India's vast generic medicine industry, drive up costs

Amendments to the Patent Rules grant more power to patent holders and may lead to an increase in the cost of treatment of critical diseases.

Mumbai
Maharashtra
India
South-africa
Japan
China
South-african
Japanese
Nandita-venkatesan
Biswajit-dhar
Phumeza-tisile
Leena-menghaney

Clear opportunity for Indian pharma firms to improve medicine access globally: Report

Report assessed the efforts of major generic and biosimilar medicine manufacturers like Hikma, Teva Viatris, Cipla, and Sun Pharma in expanding access to their essential products in low- and middle-income countries

Netherlands
Helmsley
North-yorkshire
United-kingdom
Dutch
Jayasreek-iyer
Teva-viatris
Sun-pharma
Claudia-mart
Research-programme
Development-office
Cipla

vimarsana © 2020. All Rights Reserved.